Client News

Mainz Biomed Announces Submission for FDA Breakthrough Device Designation for its Next Generation CRC Screening Test

Andera Partners Co-Leads a €63 Million Series A Round for Munich-Based Autoimmune Biotech SciRhom

MIG Capital Co-Leads €63 Million Series A Round for Autoimmune Biotech SciRhom

APEIRON Biologics to be Acquired by Ligand Pharmaceuticals for USD 100 Million

Nyxoah Has Signed a €37.5 Million Loan Facility Agreement with the European Investment Bank

Medigene AG Expands Patent Portfolio with the Patent Grant for its NY-ESO-1/LAGE 1a Targeted T Cell Receptor in China

Pentixapharm Acquires Target Discovery Business of Glycotope

Mainz Biomed Provides Half Year 2024 Corporate Update

Pentixapharm Announces Expansion of Supervisory Board with the Appointment of Distinguished Endocrinologist Marcus Quinkler

Formycon Receives FDA Approval for FYB203/ AHZANTIVE® (aflibercept-mrbb), a Biosimilar to Eylea®